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Alternative splicing is a post-transcriptional regulatory process that is attaining stronger
recognition as a modulator of gene expression. Alternative splicing occurs when the
primary RNA transcript is differentially processed into more than one mature RNAs. This
is the result of a variable deﬁnition/inclusion of the exons, the sequences that are excised
from the primary RNA to form the mature RNAs. Consequently, RNA expression can
generate a collection of differentially spliced RNAs, which may distinctly inﬂuence sub-
sequent biological events, such as protein synthesis or other biomolecular interactions.
Still the mechanisms that control exon deﬁnition and exon inclusion are not fully clari-
ﬁed. This mini-review highlights advances in this ﬁeld as well as the impact of single
nucleotide polymorphisms in affecting splicing decisions.The Glioma-associated oncogene
1, GLI1, is taken as an example in addressing the role of nucleotide substitutions for splicing
regulation.
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REGULATION OF SPLICING – CIS ELEMENTS,
TRANS FACTORS
Alternative splicing has, in recent years, been demonstrated to
occur in almost all intron-containing human genes (Pan et al.,
2008; Wang et al., 2008). However, the regulatory mechanisms
that control splice choices are not fully deciphered. Apart from
the general problem of deﬁning exonic sequences in a vast excess
of intronic DNA (Schwartz et al., 2009a), a key issue concerns
the mechanisms of the differential inclusion of exons in mature
mRNAs. The prevailing views favor that this is controlled by
the relative abundance of a limited number of splicing factors
in a particular cell type (Chen and Manley, 2009). Additionally,
alternative promoter usage may affect splicing decisions, as this
can inﬂuence the recruitment of splicing factors or the elonga-
tion rate of RNA polymerase II (Kornblihtt, 2005; Muñoz et al.,
2009). Furthermore, histone modiﬁcations are also thought to
have a role in modulating splice choices (Luco et al., 2010). More-
over, the RNA secondary structure may affect splicing decisions
(McManus and Graveley, 2011), with this claim being suggested
more than 25 years ago (Solnick, 1985). In fact, the expansion of
splicing factors, including the SR and hnRNP proteins, in higher
eukaryotes (Busch and Hertel, 2012) is in agreement with the
increased alternative splicing events in more complex organisms
(Kim et al., 2007).
In addition to this trans factor dependent regulation of splice
choices, cis sequences are also important in inﬂuencing splicing
decisions, as these are thought to act as binding sites for the splicing
factors. To start with, exons are ﬂanked by the invariant intronic
dinucleotides AG and GT, with the introns also characterized by
a polypyrimidine track near their 3′ end and the branch point
adenosine residue used for lariat formation during intron excision.
However, it is obvious that additional cis sequence information
is required in deﬁning exons and inﬂuencing their inclusion in
mRNAs. Such auxiliary sequences, which stimulate splicing are
found in both exons (exonic splicing enhancers, ESE), and introns
(intronic splicing enhancers, ISE; Aznarez et al., 2008; Lomelin
et al., 2010; Brooks et al., 2011). Moreover, sequences that inhibit
splicing have also been characterized, as exonic and intronic splic-
ing silencers (ESS and ISS; Yu et al., 2008; Zhang et al., 2008; Wen
et al., 2010). Additionally, the sequence complexity of these splic-
ing regulatory elements is highlighted by the in vivo analysis of
all possible hexamers as exonic splicing regulators, which revealed
that out of the 4,096 combinations more than half could act as
either ESE or ESS (Ke et al., 2011).
SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN
GENOMES AND ALTERNATIVE SPLICING
The advances in sequencing technologies have made possible
the complete sequence of individual human genomes at a rapid
pace (Xia et al., 2012). Consequent is the expansion of the single
nucleotide polymorphisms (SNP) entries in the dbSNP database,
which currently reachesmore than 40,000,000 validated RefSNPs1.
Thus, on the average, a SNP is present in every 75 nucleotides
within the three billion human genome sequence. Moreover, since
the human protein-coding gene content is estimated to be 2% of
the human genome, 800,000 SNPs can potentially inﬂuence gene
expression and splicing, not tomention variations outside protein-
coding genes that could alter gene regulation by mechanisms that
are still poorly understood (Visel et al., 2009).
What characterizes the SNPs that modulate splicing? Firstly,
exons that are known to be alternatively spliced, in contrast to
constitutive exons, appear to have a higher proportion of SNPs
that affect exonic splicing regulators. Additionally, ESSs are more
frequently modiﬁed by SNPs than ESEs (de Souza et al., 2011).
1http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi
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A systematic analysis of the SNPs that are known to affect splicing
revealed a number of characteristics, including a predominance of
ESS gains relative to ESE losses (Woolfe et al., 2010). These features
have been introduced in a web-based tool allowing the prediction
of the impact of SNPs on alternative splicing regulation, the Skippy
software2. In this context it is worth noting that SNPs that affect the
strength the 5′ splice site, but not the conserved GT dinucleotide,
are compensated by other regulatory signals, resulting in minimal
changes in splicing, arguing in favor of a certain robustness in
maintaining splicing patterns (Lu et al., 2011).
MUTATIONS AND GENE FUNCTION
It has generally been assumed that exonic mutations (the term
mutation refers to a polymorphism occurring in less than 1%
of the population) affect the protein product of the correspond-
ing gene by introducing a stop codon (non-sense mutation), by
altering an amino acid (missense mutation) or by changing the
translation reading frame (frameshift mutation). However, this
postulate had been challenged by the ﬁnding that nucleotide
substitutions that do not change the encoded amino acid (syn-
onymous mutation) may also alter protein structure, through an
indirect way, namely by modulating splicing patterns (Chamary
et al., 2006). This can be rationalized by either an activation of a
cryptic splice site, as in the case of the LMNA gene (Eriksson et al.,
2003), or the presence of ESE and ESS motifs, which are affected
by the introduction of a synonymous nucleotide substitution and
consequently may alter the canonical splicing pattern. In fact, it
has been convincingly argued that the genetic code can effectively
carry additional information, such as splicing signals, besides its
capacity to encode amino acids (Itzkovitz and Alon, 2007). More-
over, an analysis of 27,681 non-sense andmissense disease-causing
mutations revealed that about 25% of these actually change exonic
splicing regulators, providing evidence that alterations of splicing
patterns is not a sole characteristic of synonymous substitutions
(Sterne-Weiler et al., 2011).
THE GLIOMA-ASSOCIATED ONCOGENE 1,
GLI1 – ALTERNATIVE SPLICING
The GLI1 oncogene encompasses about 12 kb of genomic
sequences in chromosome 12q13.2–q13.3 and is composed of two
5′ non-coding exons, exons 1 and 1A, and 11 coding exons, exons
2 to 12. Two splice variants have been identiﬁed in human tis-
sues that affect coding exons, GLI1N, which lacks exons 2 and 3
(Shimokawa et al., 2008), and tGLI1, which lacks exon 3 and part
of exon 4 (Lo et al., 2009). However, variants that do or do not
include the non-coding exon 1A have also been described (Wang
and Rothnagel, 2001; Figure 1A).
In the mouse, the Gli1 gene contains a third non-coding exon,
exon 1B (Figure 1B). Interestingly, the 5′ splice site of exon 1B in
the BALB/c mouse strain contains the canonical GT dinucleotide,
while in the C57BL/6 mouse strain this is substituted with GC.
The splice signal alteration confers a preferential inclusion of exon
1B in BALB/c mice resulting in a longer 5′ UTR region. More-
over, this increased 5′ UTR length was found to have a negative
impact on the translation efﬁciency of the Gli1 mRNA, with a
2http://research.nhgri.nih.gov/skippy
FIGURE 1 | (A) Schematic representation of the exons 1 to 4 region
in the human GLI1 gene. Exons are shown by colored boxes. The GLI1
mRNA variants are indicated. The canonical translation initiation codon is
present in exon 2. In GLI1N, skipping of exons 2 and 3 results in the use
of a methionine codon in exon 4 as the initiator. In tGLI1, skipping of exon 3
and partially exon 4 does not alter the translational reading frame. The
positions of the SNPs in exon 4 that may affect exon skipping or generate
an ectopic splice site are indicated by light and dark blue triangles
respectively. (B) Schematic representation of the Gli1 exon 1B
inclusion/skipping in the mouse. BALB/c mice contain the conserved GT
dinucleotide at the exon 1B/intron 1B junction resulting in exon 1B being
mostly included in the Gli1 mRNAs. C57BL/6 mice contain a GC
dinucleotide at the exon 1B/intron 1B junction resulting in exon 1B being
mostly skipped in the Gli1 mRNAs.
consequent reduced amount of synthesized protein (Palaniswamy
et al., 2010). These observations argue that SNPs that affect splic-
ing may not necessarily alter the primary structure of the protein
product but can also have an impact on the amount of produced
protein, as a result of changes in the length/structure of the 5′ UTR
region.
THE GLIOMA-ASSOCIATED ONCOGENE 1, GLI1 – SNPs
The dbSNP database revealed that there are 249 variants in the
human GLI1 gene sequence (May 2012). From these 127 are
intronic, 32 are synonymous, 59 are non-synonymous, and 14
are in the UTR regions.
By centering on the genomic region that engages in alternative
splicing of protein-coding exons, namely exons 2 to 4 and the 100
bases ﬂanking sequence, 27 SNPs, with four being synonymous
and four non-synonymous, were identiﬁed. Moreover, the use
of the Skippy software revealed that the highest score for exon
skipping of these eight exonic SNPs is for the C to T missense
rs143548857 in exon 4. Direct experimentation will be required
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to examine whether this predicted impact on exon 4 splicing
is indeed taking place, as this will introduce a translational
frameshift.
From the 36 synonymous and non-synonymous SNPs in the
remaining protein-coding internals exons, namely exons 5 to 11,
only the C to T synonymous rs7973381 in exon 8 has an equally
high score for exon exclusion as rs143548857. Interestingly, the
size of exon 8 is 150 nucleotides, highlighting that potential exon
skipping will not initiate non-sense mediated decay (Durand and
Lykke-Andersen, 2011).
Since in the natural tGLI1 variant an alternative 3′ splice site is
used in exon 4 (Figure 1A), SNPs that could potentially medi-
ate activation of ectopic splice sites in exon 4 were examined
using the Skippy software. Interestingly, the G to A synonymous
rs139988338 in exon 4 creates a 3′ ectopic splice site with a high
score. Moreover, none of the SNPs in the remaining internal exons
of GLI1 create a 3′ ectopic splice site that has a higher score. Worth
noting is that the strength of the rs139988338-mediated 3′ ectopic
splice site in exon 4 is, in fact, higher than the natural tGLI1 alter-
native 3′ splice site, according to the MaxEnt splice site scoring
program3.
Additionally, in the non-coding but alternatively spliced exon
1A three SNPs are identiﬁed, rs10783826, rs10783827, and
rs118093490. These SNPs cannot effectively be evaluated by the
Skippy software, as the program is not optimized for non-coding
exons (Laura Elnitski, personal communication). Moreover, exon
1A is not fully annotated in the human Genome Build 37, which
automatically excludes it from the software analysis, since only
annotated exons can be used. On the other hand, manual inspec-
tion of the elicited base substitution by the three SNPs and taking
advantage of the published strength of all hexamers as ESEs and
ESSs (Ke et al., 2011) revealed that for rs10783826 and rs118093490
the nucleotide change increased the impact of the corresponding
hexamer as a silencer, while for rs10783827 the change was in
favor of an enhancer. These ﬁndings were observed irrespective of
3http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html
whether the hexamers were shifted by one base so the SNP was
placed at either the third or the fourth nucleotide position within
the hexamer. Moreover, the SROOGLE software4 (Schwartz et al.,
2009b), which uses additional programs to identify ESEs and ESSs,
revealed a similar trend. Thus, it is possible that the differential
inclusion of exon 1A may be dependent of these SNPs, and the
resulting variable length of the 5′ UTR region could have an impact
on the amount of the translatedprotein product, as previously seen
with the mouse Gli1.
CONCLUSION
Alternative splicing is a major post-transcriptional mechanism
that diversiﬁes gene expression. In addition to trans acting fac-
tors, cis regulatory sequences have also an impact in controlling
splice choices, highlighting the potential signiﬁcance of SNPs in
modulating splicing decisions. SNPs that affect splicing may be
present in both intronic and exonic regions, mapping at regula-
tory elements such as splicing enhancers and silencers. Moreover,
for exonic SNPs, not only synonymous but also missense and non-
sense SNPs can inﬂuence splice choices, providing evidence that
the major biological impact of some of these exon variants may be
on mRNA splicing rather than on protein synthesis.
Using the Glioma-associated oncogene 1, GLI1, as an example,
SNPs are predicted to have a role in controlling splicing patterns.
Interestingly, GLI1 exons that are known to engage in alterna-
tive splicing appear to preferentially encompass SNPs that may
affect splice choices. Finally, although user-friendly prediction
programs simplify the analysis of the role of SNPs in splicing reg-
ulation, the requirement of direct experimentation has not been
fully substituted.
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